Coenzyme Q10 supplementation in burn patients: a double-blind placebo-controlled randomized clinical trial

被引:1
|
作者
Kiani, Zahra [1 ,2 ]
Khorsand, Nadereh [3 ]
Beigi, Fahimeh [4 ,5 ]
Askari, Gholamreza [1 ,2 ,6 ]
Sharma, Manoj [7 ]
Bagherniya, Mohammad [1 ,2 ,6 ]
机构
[1] Isfahan Univ Med Sci, Nutr & Food Secur Res Ctr, Sch Nutr & Food Sci, Esfahan, Iran
[2] Isfahan Univ Med Sci, Sch Nutr & Food Sci, Dept Community Nutr, Esfahan, Iran
[3] Isfahan Univ Med Sci, Imam Musa Kazem Hosp, Dept Internal Med, Esfahan, Iran
[4] Isfahan Univ Med Sci, Sch Pharm & Pharmaceut Sci, Pharmaceut Biotechnol Dept, Esfahan, Iran
[5] Isfahan Univ Med Sci, Imam Muss Kazim Hosp, Res & Dev Unit, Esfahan, Iran
[6] Isfahan Univ Med Sci, Anesthesia & Crit Care Res Ctr, Esfahan, Iran
[7] Univ Nevada, Sch Publ Hlth, Dept Social & Behav Hlth, Las Vegas, NV USA
关键词
Coenzyme Q10; Burn; Inflammation; Oxidative stress; FATTY LIVER-DISEASE; INFLAMMATORY MARKERS; OXIDATIVE STRESS; Q(10) SUPPLEMENTATION; METAANALYSIS; IMPROVES;
D O I
10.1186/s13063-024-08006-y
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background Burn injuries are important medical problems that, aside from skin damage, cause a systemic response including inflammation, oxidative stress, endocrine disorders, immune response, and hypermetabolic and catabolic responses which affect all the organs in the body. The aim of this study was to determine the effect of coenzyme Q10 (CoQ10) supplementation on inflammation, oxidative stress, and clinical outcomes in burn patients. Methods In a double-blind placebo-controlled randomized clinical trial, 60 burn patients were randomly assigned to receive 100 mg CoQ10 three times a day (total 300 mg/day) or a placebo for 10 days. Inflammatory markers including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), oxidative stress markers including total antioxidant capacity (TAC), malondialdehyde (MDA) and superoxide dismutase (SOD) activity, fasting blood glucose (FBG), blood urea nitrogen (BUN), creatinine, white blood cells (WBC), and body temperature were assessed as primary outcomes and albumin, prothrombin time (PT), partial thromboplastin time (PTT), international normalized ratio (INR), other hematological parameters, blood pressure, O-2 saturation, ICU duration, and 28-mortality rate were assessed as secondary outcomes. Results Fifty-two participants completed the trial. CRP and ESR levels were not significantly different between CoQ10 and placebo groups at the end of the study (P = 0.550 and P = 0.306, respectively). No significant differences between groups were observed for TAC (P = 0.865), MDA (P = 0.692), and SOD activity (P = 0.633) as well. Administration of CoQ10 resulted in a significant increase in albumin levels compared to placebo (P = 0.031). There was no statistically significant difference between the two groups in other measured outcomes (P > 0.05). Conclusion Results showed that in patients with burn injury, CoQ10 administration had no effect on inflammatory markers and oxidative stress, although serum albumin levels were improved after supplementation. Further studies with albumin as the primary outcome are needed to confirm this finding.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Coenzyme Q10 supplementation in burn patients: a double-blind placebo-controlled randomized clinical trial
    Zahra Kiani
    Nadereh Khorsand
    Fahimeh Beigi
    Gholamreza Askari
    Manoj Sharma
    Mohammad Bagherniya
    Trials, 25
  • [2] A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
    McGarry, Andrew
    McDermott, Michael
    Kieburtz, Karl
    de Blieck, Elisabeth A.
    Beal, Flint
    Marder, Karen
    Ross, Christopher
    Shoulson, Ira
    Gilbert, Peter
    Mallonee, William M.
    Guttman, Mark
    Wojcieszek, Joanne
    Kumar, Rajeev
    LeDoux, Mark S.
    Jenkins, Mary
    Rosas, H. Diana
    Nance, Martha
    Biglan, Kevin
    Como, Peter
    Dubinsky, Richard M.
    Shannon, Kathleen M.
    O'Suilleabhain, Padraig
    Chou, Kelvin
    Walker, Francis
    Martin, Wayne
    Wheelock, Vicki L.
    McCusker, Elizabeth
    Jankovic, Joseph
    Singer, Carlos
    Sanchez-Ramos, Juan
    Scott, Burton
    Suchowersky, Oksana
    Factor, Stewart A.
    Higgins, Donald S., Jr.
    Molho, Eric
    Revilla, Fredy
    Caviness, John N.
    Friedman, Joseph H.
    Perlmutter, Joel S.
    Feigin, Andrew
    Anderson, Karen
    Rodriguez, Ramon
    McFarland, Nikolaus R.
    Margolis, Russell L.
    Farbman, Eric S.
    Raymond, Lynn A.
    Suski, Valerie
    Kostyk, Sandra
    Colcher, Amy
    Seeberger, Lauren
    NEUROLOGY, 2017, 88 (02) : 152 - 159
  • [3] Coenzyme Q10 supplementation and diastolic heart functions in hemodialysis patients: A randomized double-blind placebo-controlled trial
    Turk, Suleyman
    Baki, Aysegul
    Solak, Yalcin
    Kayrak, Mehmet
    Atalay, Huseyin
    Gaipov, Abduzhappar
    Aribas, Alpay
    Akilli, Hakan
    Biyik, Zeynep
    Okudan, Nilsel
    Gokbel, Hakki
    HEMODIALYSIS INTERNATIONAL, 2013, 17 (03) : 374 - 381
  • [4] Randomized, Double-Blind Placebo-Controlled Trial of Coenzyme Q10 in Patients with Acute Myocardial Infarction
    Ram B. Singh
    Gurpreet S. Wander
    Amit Rastogi
    Pradeep K. Shukla
    Adarsh Mittal
    Jagdish P. Sharma
    Shiv K. Mehrotra
    Raj Kapoor
    Raj K. Chopra
    Cardiovascular Drugs and Therapy, 1998, 12 : 347 - 353
  • [5] Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction
    Singh, RB
    Wander, GS
    Rastogi, A
    Shukla, PK
    Mittal, A
    Sharma, JP
    Mehrotra, SK
    Kapoor, R
    Chopra, RK
    CARDIOVASCULAR DRUGS AND THERAPY, 1998, 12 (04) : 347 - 353
  • [6] Randomized, double-blind, placebo-controlled trial of coenzyme Q10 in isolated systolic hypertension
    Burke, BE
    Neuenschwander, R
    Olson, RD
    SOUTHERN MEDICAL JOURNAL, 2001, 94 (11) : 1112 - 1117
  • [7] Safety assessment of coenzyme Q10 (Kaneka Q10) in healthy subjects: A double-blind, randomized, placebo-controlled trial
    Ikematsu, H
    Nakamura, K
    Harashima, S
    Fujii, K
    Fukutomi, N
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2006, 44 (03) : 212 - 218
  • [8] Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q10 in Parkinson disease
    Storch, Alexander
    Jost, Wolfgang H.
    Vieregge, Peter
    Spiegel, Joerg
    Greulich, Wolfgang
    Durner, Joachim
    Mueller, Thomas
    Kupsch, Andreas
    Henningsen, Henning
    Oertel, Wolfgang H.
    Fuchs, Gerd
    Kuhn, Wilfried
    Niklowitz, Petra
    Koch, Rainer
    Herting, Birgit
    Reichmann, Heinz
    ARCHIVES OF NEUROLOGY, 2007, 64 (07) : 938 - 944
  • [9] Effects of coenzyme Q10 supplementation on matrix metalloproteinases and DAS-28 in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled clinical trial
    Seyed Mostafa Nachvak
    Beitollah Alipour
    Aida Malek Mahdavi
    Mir Amir Aghdashi
    Hadi Abdollahzad
    Yahya Pasdar
    Mehnoosh Samadi
    Roghayeh Mostafai
    Clinical Rheumatology, 2019, 38 : 3367 - 3374
  • [10] Effects of coenzyme Q10 supplementation on matrix metalloproteinases and DAS-28 in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled clinical trial
    Nachvak, Seyed Mostafa
    Alipour, Beitollah
    Mahdavi, Aida Malek
    Aghdashi, Mir Amir
    Abdollahzad, Hadi
    Pasdar, Yahya
    Samadi, Mehnoosh
    Mostafai, Roghayeh
    CLINICAL RHEUMATOLOGY, 2019, 38 (12) : 3367 - 3374